RaffaellaFaraoni Ph.D.

Associate

San Diego + 1.858.314.1153

Connect:

Share

Raffaella Faraoni's practice focuses on the development and management of global patent portfolios in the areas of pharmaceuticals, chemicals, and biotechnology. A particular emphasis of her practice is advising clients regarding intellectual property matters for small molecule drugs. Raffaella has experience assisting in opposition proceedings before the European Patent Office, IP litigation, inter partes review (IPR) proceedings, and trade secrets litigation. In addition, she helps clients in preparing and submitting patent term extensions.

Raffaella also advises clients on due diligence matters, including providing patentability, validity, and freedom-to-operate analysis, in association with clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities. Representative clients include BioMarin Pharmaceutical, Puma Biotechnology, and Idenix Pharmaceuticals (a subsidiary of Merck & Co., Inc.). Raffaella counseled and assisted clients in developing patent portfolios for INGREZZA®, NERLYNX®, and Auryxia®.

Raffaella is actively involved in the Firm's pro bono initiative against human trafficking.

Prior to joining Jones Day, Raffaella worked as a medicinal chemist at Ambit Biosciences and the Genomic Institute of the Novartis Research Foundation (GNF), where her research area focused on the design and synthesis of kinase and ion channels small molecule inhibitors for the treatment of cancer and chronic pain.

She is coauthor of several peer-reviewed scientific articles and a co-inventor of a number of issued patents and patent applications.

Experience

  • Puma Biotechnology defends European patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer in opposition proceedingsJones Day represents Puma Biotechnology, Inc. in European opposition proceedings initiated by Hexal to defend a patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer.
  • BioMarin expands rare disease oligonucleotide therapeutic patent portfolio following worldwide settlement with SareptaJones Day represents BioMarin Pharmaceutical Inc. in prosecution of patent portfolio directed to oligonucleotide therapeutic agents for treatment of rare genetic diseases, including Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
  • Takeda acquires Ariad Pharmaceuticals for $5.2 billionJones Day advised Takeda Pharmaceuticals U.S.A., Inc. on intellectual property matters relating to its $5.2 billion acquisition of Ariad Pharmaceuticals.
  • Idenix establishes patent portfolio related to nucleoside analog antiviral drugsJones Day represents Idenix Pharmaceuticals, Inc. in the management and development of a patent portfolio related to nucleoside analog antiviral drugs.
    • View All

    August 2017 Blogs

    Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog

    March 2017

    In an IPR, the Burden of Persuasion in an Obviousness Challenge Never Shifts to Patentee

    January 2017 Blogs

    Routine Trial-and-Error Approach to Protein Formulation Is Not Sufficient to Establish Obviousness Absent a Reasonable Expectation of Success in Achieving the Claimed Formulation, PTAB Litigation Blog
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.